***Background.*** LT patients are at higher risk of CDI compared to other hospitalized patients. Since LT patients with CCA often require antibacterial therapy for various infections, they may be at increased risk of CDI. However, the epidemiology, risk factors and impact of CDI in LT recipients with CCA have not been studied. We describe the epidemiology and risk factors for CDI and assess its impact on patient outcomes among LT patients with CCA.

***Methods.*** We conducted a retrospective cohort study of patients who underwent neoadjuvant chemo-radiotherapy followed by LT for CCA during 2004-2013 at a single tertiary referral center.

***Results.*** The population consisted of 124 patients who were followed for median duration of 4.2 years (interquartile range (IQR) 1.5-6.7 years). 15.9% developed CDI within 9.3 years post-transplant (19 episodes in 15 patients).10 (67%) were male. Thirteen (68%) were community-onset CDI. Initial treatment regimen consisted of oral metronidazole in 11 (58%) and oral vancomycin in 8 (42%) episodes. 4 patients developed recurrent CDI. Recurrent CDI was treated with oral metronidazole (50%) and oral vancomycin (50%). No patient died from CDI and none developed toxic megacolon or required surgical intervention. On univariable analysis, LT patients with history of a pre-transplant infection (within 6 months pre-transplant) had lower risk of post-transplant CDI (HR 0.3 (0.1-0.9); P = 0.04). Post-transplant CDI was associated with higher mortality when adjusted for recurrent CCA (HR 4.6 (1.4-15.2); P = 0.01).

***Conclusion.*** CDI is a common infectious complication after LT for CCA, and is associated with a higher risk of mortality. Its prevention, through antimicrobial stewardship, may improve the outcomes of LT patients with CCA.

***Disclosures.*** **All authors:** No reported disclosures.

[^1]: **Session:** 47. Transplant Infectious Diseases

[^2]: Thursday, October 9, 2014: 12:30 PM
